Document Detail


Anticancer drugs in liposomal nanodevices: a target delivery for a targeted therapy.
MedLine Citation:
PMID:  22978336     Owner:  NLM     Status:  Publisher    
Abstract/OtherAbstract:
For many years, nanocarriers have been investigated to modify pharmacokinetics and biodistribution of various active molecules. In the cancer domain, one of the biggest challenges still remains the improvement of the therapeutic index, often too low, for the majority of antitumor drugs. The application of nanotechnologies for the treatment and the diagnosis of cancers are nowadays currently developed, or under development, and liposomes play an important role in the history of nanodevices. Because of their high degree of biocompatibility, lipid nanosystems have been used to improve pharmacological profiles of various anticancer drugs otherwise discarded because of their low water solubility, poor bioavailability or either fragile and subjected to rapid biotransformations. This review aims at introducing an overview of the last 40 years of liposome researches until the last liposomal formulations commercially available or undergoing clinical trials. Liposome properties will be described, with a particular emphasis over the last generation of carriers appreciated for their active targeting characteristics. Researchers foresee a remarkable impact of nanotechnologies in the field of medicine; this review will try to summarize the main concepts over liposome domain, which can count on encouraging results as target therapy associated with targeted delivery.
Authors:
Giorgia Urbinati; Véronique Marsaud; Jack-Michel Renoir
Related Documents :
24590166 - In-vivo evaluation of tamoxifen-loaded microspheres based on mixtures of poly (d,l-lact...
19392926 - New antiplatelet drugs: beyond aspirin and clopidogrel.
23799586 - Metallomics for drug development: an integrated ce-icp-ms and icp-ms approach reveals t...
20596466 - Accelerated hydrolysis of aspirin using alternating magnetic fields.
23991146 - Glucocorticosteroids in nano-sterically stabilized liposomes are efficacious for elimin...
16271446 - Pharmacogenetics of irinotecan metabolism and transport: an update.
Publication Detail:
Type:  JOURNAL ARTICLE     Date:  2012-9-11
Journal Detail:
Title:  Current topics in medicinal chemistry     Volume:  -     ISSN:  1873-4294     ISO Abbreviation:  Curr Top Med Chem     Publication Date:  2012 Sep 
Date Detail:
Created Date:  2012-9-17     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101119673     Medline TA:  Curr Top Med Chem     Country:  -    
Other Details:
Languages:  ENG     Pagination:  -     Citation Subset:  -    
Affiliation:
UMR CNRS 8612, laboratory of Molecular Pharmacology of antitumor drugs; Faculty of Pharmacy; 5, Rue JB Clément, F-92296 Chatenay-Malabry, FRANCE. 2Paris-Sud 11 University; F-91405 Orsay, France. Giorgia.URBINATI@igr.fr.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Progress in Strategies for Dosage Regimen Individualization.
Next Document:  On Determining the MTD for Phase I Trials in Pediatric Oncology.